Search
Cogent Biosciences Inc
COGTAdd to Watchlist
34.540USD
+0.870+2.58%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
5.90BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Cogent Biosciences Inc is 8.62, ranking 93 out of 389 in the Biotechnology & Medical Research industry. The average price target is 49.00, with a high of 65.00 and a low of 34.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
53.545
Target Price
+55.02%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Cogent Biosciences Inc
COGT
13
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Cogent Biosciences Inc's price target?
Analysts forecast that Cogent Biosciences Inc's price target is USD 49.00, with the highest forecast at USD 65.00 and the lowest forecast at USD 34.00.
How have Cogent Biosciences IncCOGT's recent earnings per share performed?
The market expectation was USD -0.53, while Cogent Biosciences IncCOGT's earnings per share (EPS) for the previous quarter was USD -0.59. EPS for the next quarter is expected at USD -0.57.
What is the analyst rating for Cogent Biosciences Inc?
Based on the ratings of Cogent Biosciences Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
